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Abstract
Introduction: Sepsis-induced immunosuppression may result in death. The mechanisms of immune suppression
include loss of macrophage and monocyte expression of the major histocompatibility complex, increased anti-
inflammatory cytokine expression and decreased expression of proinflammatory cytokines. In this study, we sought
to determine the mechanisms of immune suppression in severe sepsis by repeated detection.
Methods: We designed this prospective observational study to measure monocyte human leukocyte antigen
(HLA)-DR expression, plasma cytokine levels and cytokine responses on days 1 and 7 in stimulated peripheral blood
mononuclear cells (PBMCs) of healthy controls and patients with severe sepsis.
Results: Of the 35 enrolled patients, 23 survived for 28 days and 12 died, 6 of whom died within 7 days. Plasma
levels of IL-1b, IL-6, IL-10, IL-17, transforming growth factor (TGF)-b1 and TNF-a were higher, but plasma IL-12 level
was lower in septic patients than those in controls. Day 1 plasma levels of IL-1b, IL-6, IL-10 and TGF-b1 in
nonsurvivors were higher than those in survivors. Day 7 plasma IL-10 levels in nonsurvivors were higher than in
survivors. IL-1b response was higher, but IL-12 and TNF-a responses were lower in septic patients than in controls.
Day 1 IL-6 response was lower, but day 1 TGF-b1 response was higher in nonsurvivors than in survivors. Plasma IL-
6 and IL-10 levels were decreased in survivors after 6 days. IL-6 response was decreased in survivors after 6 days,
but IL-12 response was increased. Monocyte percentage was higher, but positive HLA-DR percentage in monocytes
and mean fluorescence intensity (MFI) of HLA-DR were lower in septic patients than in controls. MFI of HLA-DR
was increased in survivors after 6 days.
Conclusions: Monocyte HLA-DR expression and IL-12 response from PBMCs are restored in patients who survive
severe sepsis.
Keywords: interleukin 12, interleukin 6, human leukocyte antigen-DR, peripheral blood mononuclear cells, severe
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Introduction
Sepsis is characterized by an acute release of many
inflammatory mediators. The balance between pro- and
anti-inflammatory mediators influences the survival rate
of septic patients. In severe sepsis, immune system failure
and sepsis-induced immunosuppression may result in
death [1,2]. Loss of macrophage and monocyte expres-
sion of the major histocompatibility complex is one of
the mechanisms involved, as is diminished surface
expression of human leukocyte antigen-DR (HLA-DR)
on monocytes [3]. However, not all studies have shown
such results [4,5].
A shift from inflammatory to anti-inflammatory cyto-
kines is another mechanism of immune suppression in
sepsis. IL-10 level is increased in patients with sepsis and
can predict mortality [6]. Nonetheless, IL-10 production
from peripheral blood mononuclear cells (PBMCs) in
patients with severe sepsis remains unclear. Transforming
growth factor (TGF)-b1 can downregulate T-cell, macro-
phage and granulocyte responses, whereas increased
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plasma TGF-b1 level is associated with severe disease and
mortality in patients with severe pneumonia [7]. Although
baseline plasma levels of TGF-b1 are significantly higher
in survivors with severe sepsis [8], the correlation of out-
come with TGF-b1 production by PBMCs in patients with
severe sepsis is lacking.
Diminished proinflammatory cytokine responses also
cause immune failure. Low IL-12 production by lipopoly-
saccharide (LPS)-stimulated PBMCs has been detected in
nonsurvivors with severe sepsis [9]. However, plasma IL-
12 levels are similar in survivors and nonsurvivors with
severe sepsis [10,11]. It may be that high local IL-12 pro-
duction in infected areas is more important for infection
control. The correlation of low IL-12 response with mor-
tality in severe sepsis should be confirmed.
There is a recent emerging cytokine, IL-17, which acts as
a potent inflammatory cytokine in vitro and in vivo [12].
The relationship of circulatory IL-17 level and IL-17
response in humans with severe sepsis is still unknown.
IL-1b upregulates adhesion molecule expression and
enhances neutrophil and macrophage emigration, while
TNF-a enhances proinflammatory cytokine production
and natural killer (NK) cell function. The functions of IL-6
in sepsis include induction of acute phage protein produc-
tion and T- and B-cell differentiation and growth. How-
ever, serial responses of IL-1b, TNF-a and IL-6 from
PBMCs still need to be elucidated in patients with severe
sepsis. Thus, this observational study was designed with
repeated blood samplings to determine whether immune
suppression is different between survivors and nonsurvi-
vors with severe sepsis.
Materials and methods
Participants and definitions
From July 2008 to June 2009, 35 patients who were
admitted to a 20-bed ICU in a regional teaching referral
hospital for severe sepsis were enrolled in this study. Six
nonsurvivors died within 7 days. “Systemic inflammatory
response syndrome” (SIRS) was defined if the patient met
two or more of the following criteria: (1) body temperature
> 38°C or < 36°C, (2) respiratory rate > 20 breaths/minute,
(3) heart rate > 90 bpm and (4) white blood cell count >
12,000/μl or < 4,000/μl or > 10% bands. “Sepsis” was
defined as SIRS according to a confirmed infectious etiol-
ogy. To validate experimental findings, 22 men and 8
women with mean age of 60.8 ± 1.9 years old who visited
our health evaluation center for examinations were
enrolled as healthy controls.
“Severe sepsis” was defined according to the consensus
criteria [13,14] for sepsis with dysfunction of one or
more organs, such as shock, respiratory failure, acute
renal failure, jaundice and thrombocytopenia. “Septic
shock” was defined as sepsis-induced hypotension unre-
sponsive to fluid resuscitation. “Respiratory failure” was
defined as ventilation dysfunction requiring invasive ven-
tilatory support. “Acute renal failure” was defined as a
rapid increase in creatinine level (> 0.5 mg/dl). “Jaundice”
was defined as hyperbilirubinemia (total bilirubin > 2
mg/dl). “Thrombocytopenia” was defined as a platelet
count < 150,000/μl. Disease severity was assessed accord-
ing to Acute Physiology and Chronic Health Evaluation
(APACHE) II score [15].
Standard treatment according to published guidelines
was provided to all patients [16,17]. The Institutional
Review Board at Chang Gung Memorial Hospital
approved this study (96-1465B), and the patients’ close
family members provided informed consent. Patients
who survived longer than 28 days after ICU admission
were defined as survivors. All comorbidities and medical
histories were recorded.
Plasma and peripheral blood mononuclear cell
preparation
Whole blood (10 ml) was obtained from each patient at
8:30 AM within 48 hours of admission to the ICU and
immediately mixed with heparin. Whole blood from con-
trols was drawn between 8:00 and 8:30 AM and also
immediately mixed with heparin. The day of first blood
sampling was defined as day 1. A second blood sample
was obtained on day 7. Second blood sampling was not
done in controls. Plasma samples were obtained from 2
ml of whole blood and stored at -80°C until use. PBMCs
were isolated via differential centrifugation over Ficoll-
Paque (Amersham Biosciences, Uppsala, Sweden) from
8 ml of residual whole blood within 2 hours of collection.
Monocyte human leukocyte-DR measurement by flow
cytometry
The 2.5 × 105 PBMCs were suspended in 50 μl of PBS and
incubated in the dark for 15 minutes at room temperature
with 20 μl of HLA-DR peridinin-chlorophyll-protein com-
plex (HLA-DRPerCP), CD11b phycoerythrin (CD11bPE) and
CD14 fluorescein isothiocyanate (CD14FITC) antibodies
(BD Biosciences/Pharmingen, San Diego, CA, USA). Then
the cells were resuspended in 500 μl of PBS. The mono-
cytes were detected by using a three-color flow cytofluori-
meter (Beckman Coulter, CA, USA) with positive
CD11bPE and CD14FITC. Monocyte HLA-DR measure-
ment was expressed as percentages of HLA-DR-positive
monocytes and as means of fluorescence intensities
(MFIs) related to the entire monocyte population, reflect-
ing the HLA-DR density per cell (Figure 1). Cytofluori-
metric analysis was performed with Kaluza Analysis
version 1.1 software (Beckman Coulter, Brea, CA, USA).
Cell culture
The 5 × 105 PBMCs were plated in two wells of a flat-
bottomed 24-well plate (Nunclon™Δ; Nunc A/S,
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Roskilde, Denmark) in 1 ml of sterile RPMI 1640 tissue
culture medium containing 5% heat-inactivated bovine
serum, 1 mM L-glutamine (Gibco, Grand Island, NY,
USA) and 1 mM sodium pyruvate. The cells in the first
well were not stimulated or treated. The cells in the sec-
ond well were stimulated with 1 pg/μl LPS (Sigma, St
Louis, MO, USA). The plate was incubated at 37°C in
5% CO2 for 24 hours. Supernatants of the culture wells
were sampled and stored at -80°C until use.
Measurement of cytokine levels
IL-10 levels of plasma and supernatants were measured
with a human ELISA kit (Pierce Biotechnology, Rockford,
IL, USA), according to the manufacturer’s instructions.
Figure 1 Flow cytometry of cells from a septic patient and a healthy control. Monocytes were identified in gated A cells in the scatterplot
of forward scatter (FS) and side scatter (SS) with positive CD14 and CD11b (area C). Human leukocyte antigen-DR (HLA-DR) expression is
represented in the histogram. Area D was set as positive HLA-DR. In this patient, the percentage of monocytes is 3.33%. HLA-DR was expressed
in 66.97% of monocytes. The mean fluorescence intensity of HLA-DR is 1.77. In the control, the percentage of monocytes is 4.51%. HLA-DR is
expressed in 96.45% of monocytes. The mean fluorescence intensity of HLA-DR is 2.39. FITC = fluorescein isothiocyanate.
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IL-6, TGF-b1 and IL-17 levels of plasma and superna-
tants were measured with human ELISA kits (R&D
Systems, Inc., Minneapolis, MN, USA), according to
manufacturer’s instructions. IL-12, TNF- a and IL-1 b
levels of plasma and supernatants were measured with
human ELISA kits (BD Biosciences), according to the
manufacturer’s instructions. Cytokine responses were
measured as the difference in supernatant levels with
and without stimulation. Negative responses were set as
0 pg/ml.
Statistical analysis
Statistical analysis was performed with Statistical Package
for the Social Sciences (SPSS) for Windows version 11.0.1
software (SPSS Inc, Chicago, IL, USA). Differences for
continuous variables between two groups were analyzed
using the Mann-Whitney U test, and differences between
categorical variables were analyzed using the c2 test or
Fisher’s exact test. Differences for continuous variables in
the same subjects were analyzed using the Wilcoxon
signed-rank test. P < 0.05 was considered statistically
significant.
Results
Of the 35 enrolled subjects with severe sepsis, 23 sur-
vived for 28 days and 12 died, 6 of whom died within 7
days. There were no significant differences in age, gender,
APACHE II score, medical history, infection source or
initial antibiotic susceptibility between survivors and
nonsurvivors. The clinical characteristics are shown in
Table 1. Nonsurvivors had higher percentages of septic
shock, thrombocytopenia and bacteremia than survivors.
The percentages of new arrhythmia, gastrointestinal
bleeding, acute renal failure and jaundice were similar
between the two groups.
Plasma cytokine levels and cytokine responses among
survivors, nonsurvivors and controls
Day 1 plasma levels of IL-1b, IL-6, IL-10 and TGF-b1 in
nonsurvivors were significantly higher than those in survi-
vors (Table 2). There were no differences in day 1 plasma
levels of IL-12, IL-17 and TNF-a or in day 7 levels of IL-
1b, IL-6, IL-12, IL-17, TGF-b1 and TNF-a between the
two groups. Day 7 plasma IL-10 levels were significantly
higher in nonsurvivors than in survivors. Day 1 plasma
levels of IL-1b, IL-6, IL-10, IL-17, TGF-b1 and TNF-a in
septic patients were significantly higher than those in con-
trols. Day 1 plasma IL-12 levels in septic patients were sig-
nificantly lower than in controls.
Day 1 IL-6 response was significantly lower and day 1
TGF-b1 response was significantly higher in nonsurvivors
than in survivors. There were no differences in day 1
cytokine responses of IL-1b, IL-10, IL-12, IL-17 and
TNF-a or in all detected cytokine responses on day 7
between survivors and nonsurvivors. Day 1 IL-1b
responses in septic patients were significantly higher than
those in controls. Day 1 IL-12 and TNF-a responses in
septic patients were significantly lower than those in
controls.
Plasma cytokine levels and cytokine responses between
day 1 and day 7
Plasma IL-6 and IL-10 levels were significantly decreased
in survivors after 6 days (Figures 2A and 2B). There were
no changes in plasma levels of IL-1b, IL-12, IL-17, TGF-
b1 and TNF-a in survivors. After 6 days, IL-6 responses
were also significantly decreased in survivors (Figure 3A),
while IL-12 responses were significantly increased in survi-
vors (Figure 3B). There were no changes in cytokine
responses of IL-1b, IL-10, IL-17, TGF-b1 and TNF-a in
survivors and no changes in all detected plasma cytokine
levels and cytokine responses in nonsurvivors after 6 days.
HLA-DR expression among survivors, nonsurvivors and
controls on days 1 and 7
One severe sepsis nonsurvivor did not undergo flow cyto-
metry analysis, owing to insufficient PBMCs. There were
no differences in monocyte percentage, positive HLA-DR
percentage in monocytes or MFI of HLA-DR between sur-
vivors and nonsurvivors on day 1 or day 7 (Table 3). The
MFI of HLA-DR was significantly increased in survivors
after 6 days. The monocyte percentage and positive HLA-
DR percentage in monocytes were similar in survivors
between days 1 and 7. However, there were no differences
in monocyte percentage, positive HLA-DR percentage in
monocytes or MFI of HLA-DR in nonsurvivors between
days 1 and 7. Day 1 monocyte percentage in septic
patients was significantly higher than that in controls. Day
1 positive HLA-DR percentage in monocytes and MFI of
HLA-DR in septic patients were significantly lower than
those in controls.
Discussion
Inflammation is an important response to infection, as it
induces clearing of invasive pathogens. Monocytes link
innate immunity and are key immune cells in sepsis. As
antigen-presenting cells, monocytes and macrophages are
the first host defense against infection. Reduced HLA-DR
expression reflects sepsis-induced immunosuppression
and is associated with clinical outcome [8,18]. Lympho-
cyte apoptosis is increased in CD4+ and CD8+ T cells in
septic compared to nonseptic patients [19]. Decreased
lymphocyte counts result in an increased percentage of
monocytes in PBMCs. Decreased HLA-DR expression in
septic patients is well-known [3]. All of the above data
are similar to our findings of higher monocyte percentage
and lower HLA-DR expression in patients with severe
sepsis compared to healthy controls.
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Our current study demonstrates that patients with
serial increases of HLA-DR expression in monocytes
have favorable outcomes in severe sepsis. A weak trend
of HLA-DR expression recovery is associated with
increased risk of secondary infection in ICU patients,
such that the lower the slope of HLA-DR expression
recovery is, the higher the incidence of first secondary
infection will be [20]. Thus, recovery of HLA-DR
expression may represent recovery from sepsis-induced
immunosuppression and improved outcome. In this
study, there was no difference in monocyte percentage,
positive HLA-DR percentage in monocytes and MFI of
HLA-DR between survivors and nonsurvivors on day 1
or day 7. This is different from the results of the studies
by Hynninen et al. [21] and Lekkou et al. [8], who
reported that HLA-DR expression upon admission is
significantly higher in survivors with severe sepsis than
in nonsurvivors. However, our results are similar to
those reported by Monneret et al. [22] in that HLA-DR
expression was not significantly different on days 1 and
2 between survivors and nonsurvivors with septic shock.
The conflicting results may be due to different times of
blood sampling (early vs late). Among the study
patients, the time of blood sampling was upon ICU
admission, not in the early stage of severe sepsis. In this
investigation, some patients were admitted to the ICU
while the sepsis was in the late stage and some patients
were admitted to the ICU when the sepsis was in the
early stage. The analysis of trends of HLA-DR expres-
sion in each subgroup may be better than the analysis
of differences between subgroups.
Weighardt et al. [23] found impaired preoperative
monocyte IL-12 secretion in patients who developed
fatal postoperative sepsis. Weighardt et al.’s data suggest
Table 1 Clinical characteristics in survivors and nonsurvivors
Patient characteristics Survivors (n = 23) Nonsurvivors (n = 12)
Mean age, years (± SEM) 73.0 ± 3.2 73.2 ± 3.3
Males, n (%) 15 (65) 9 (75)
Mean APACHE II score (± SEM) 27.1 ± 1.6 32.7 ± 2.1
History, n (%)
Chronic obstructive pulmonary disease 8 (35) 1 (8)
Heart failure 3 (13) 0 (0)
Pneumoconiosis 2 (9) 1 (8)
Bronchiectasis 2 (9) 0 (0)
Hypertension 8 (35) 2 (17)
Diabetes mellitus 4 (17) 3 (25)
Previous cerebral vascular accident 5 (22) 2 (17)
End-stage renal disease 1 (4) 1 (8)
Liver cirrhosis 1 (4) 3 (25)
Active malignancy 3 (13) 5 (42)
Infection source, n (%)
Pneumonia 19 (83) 10 (84)
Urinary tract infection 4 (17) 0 (0)
Catheter infection 0 (0) 1 (8)
Biliary tract infection 0 (0) 1 (8)
Initial antibiotics for pathogens, n (%)
Sensitive 12 (52) 6 (50)
Resistant 6 (26) 6 (50)
No pathogen isolated 5 (22) 0 (0)
Adverse events, n (%)
New arrhythmia 1 (4) 2 (17)
Gastrointestinal bleeding 3 (13) 2 (17)
Acute renal failure 11 (48) 8 (67)
Shock 15 (65) 12 (100)*
Thrombocytopenia 5 (22) 7 (58)*
Jaundice 0 (0) 2 (17)
Bacteremia 1 (4) 4 (33)*
SEM = standard error of the mean; APACHE II = Acute Physiology and Chronic Health Evaluation II. *P < 0.05 compared with survivors by the Mann-Whitney U
test, c2 test or Fisher’s exact test.
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that partial preoperative monocyte paralysis may impair
host defenses against postoperative infection, resulting
in increased risk of lethal sepsis. Our current study is
the first to report serial increases in IL-12 response
from PBMCs in survivors with severe sepsis. This result
is similar to the results reported by Stanilova et al. [9],
who showed that survivors with severe sepsis produce
more IL-12 from LPS-stimulated PBMCs than
Table 2 Plasma cytokine levels and cytokine responses on days 1 and 7 in survivors, nonsurvivors and controls
Patient characteristics Survivors (n = 23) Nonsurvivors (n = 12) All patients (n = 35) Controls (n = 30)
Day 1
Plasma IL-1b 0.1 (0.0 to 2.4) 1.2*(0.0 to 20.6) 0.5 0.0 to 20.6 0.0† (0.0 to 37.7)
IL-1b response 203.8 (0.2 to 220.9) 193.7 (97.4 to 212.8) 203.1 (0.2 to 220.9) 89.3† (0.9 to 209.5)
Plasma IL-6 level 54.6 (4.6 to 442.0) 238.5*(6.5 to 422.0) 73.7 (4.6 to 442.0) 0.8† (0.0 to 64.9)
IL-6 response 451.4 (2.3 to 491.1) 381.4*(88.2 to 444.8) (389.1 (2.3 to 491.1) 377.8 (2.1 to 670.7)
Plasma IL-10 level 13.9 (0.0 to 110.3) 45.1*(0.0 to 1077.6) 36.5 (0.0 to 1077.6) 3.5† (0.0 to 40.0)
IL-10 response 177.5 (0.0 to 859.7) 283.1 (1.1 to 855.4) 190.0 (0.0 to 859.7) 282.9 (0.0 to 627.8)
Plasma IL-12 level 0.0 (0.0 to 195.9) 6.3 (0.0 to 233.6) 0.0 (0.0 to 233.6) 60.7† (3.4 to 541.6)
IL-12 response 198.4 (0.0 to 1,626.8) 40.7 (0.0 to 1004.9) 152.7 (0.0 to 1,626.8) (202.0† (0.0 to 1,300.4)
Plasma IL-17 level 8.7 (0.0 to 131.6) 14.4 (0.0 to 197.0) 9.3 (0.0 to 197.0) 0.0† (0.0 to 15.5)
IL-17 response 0.0 (0.0 to 47.3) 0.0 (0.0 to 13.9) 0.0 (0.0 to 47.3) 0.0 (0.0 to 11.4)
Plasma TGF-b1 level 3,498.4 (930.4 to 9,214.1) 5,789.7*(2,501.8 to 15,870.3) 4,151.2 (930.4 to 15,870.3) 3,034.1† (381.5 to 7,890.4)
TGF-b1 response 0.0 (0.0 to 293.9) 96.5*(0.0 to 374.1) 0.0 (0.0 to 374.1) 7.4 (0.0 to 211.2)
Plasma TNF-a level 0.0 (0.0 to 3.5) 0.0 (0.0 to 111.7) 0.0 (0.0 to 111.7) 0.0† (0.0 to 0.5)
TNF-a response 409.2 (30.5 to 515.9) 383.3 (89.3 to 435.4) 399.2 (30.5 to 515.9) 617.3† (0.0 to 725.6)
Day 7 (n = 23) (n = 6) (n = 29)
Plasma IL-1b 0.3 (0.0 to 35.4) 0.6 (0.2 to 2.6) 0.4 (0.0 to 35.4)
IL-1b response 199.1 (153.7 to 214.9) 201.0 (110.0 to 209.0) 199.6 (110.0 to 214.9)
Plasma IL-6 level 30.1 (6.0 to 170.2) 68.3 (14.2 to 274.8) 30.1 (6.0 to 274.8)
IL-6 response 414.0 (32.2 to 470.1) 378.8 (286.5 to 446.3) 401.1 (32.2 to 470.1)
Plasma IL-10 level 0.0 (0.0 to 89.1) 63.2*(35.4 to 96.9) 5.5 (0.0 to 96.9)
IL-10 response 181.6 (86.0 to 710.5) 303.2 (0.0 to 480.9) 213.1 (0.0 to 710.5)
Plasma IL-12 level 0.0 (0.0 to 217.5) 0.0 (0.0 to 43.3) 0.0 (0.0 to 217.5)
IL-12 response 332.1 (30.5 to 3,097.3) 127.2 (22.7 to 705.8) 329.1 (22.7 to 3,097.3)
Plasma IL-17 level 6.4 (0.0 to 23.2) 10.6 (0.0 to 70.6) 6.4 (0.0 to 70.6)
IL-17 response 0.0 (0.0 to 16.2) 0.0 (0.0 to 27.8) 0.0 (0.0 to 27.8)
Plasma TGF- b1 level 3,164.2 (15,66.7 to 11,100.5) 5,065.2 (2,589.8 to 12,343.1) 3,995.4 (1,566.7 to 12,343.1)
TGF-b1 response 0.0 (0.0 to 173.7) 0.0 (0.0 to 133.6) 0.0 (0.0 to 173.7)
Plasma TNF-a level 0.0 (0.0 to 2.8) 0.0 (0.0 to 5.2) 0.0 (0.0 to 5.2)
TNF-a response 405.4 (198.2 to 521.9) 410.7 (56.4 to 432.7) 406.4 (56.4 to 521.9)
TGF = transforming growth factor. All data are medians (ranges) in pictograms per milliliter. *P < 0.05 compared with survivors by Mann-Whitney U test. †P <
0.05 compared with all patients with severe sepsis by Mann-Whitney U test.
Figure 2 Plasma IL-6 and IL-10 levels were significantly decreased after 6 days in survivors with severe sepsis. There was no difference
in plasma levels of (A) IL-6 and (B) IL-10 between day 1 and day 7 in nonsurvivors with severe sepsis.
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nonsurvivors. The main immunological function of IL-
12 is to enhance native T-lymphocyte differentiation to
type 1 T helper (Th1) cells. Th1 cells secrete interferon-
g, which regulates macrophage and NK cell activation,
stimulates immunoglobulin secretion by B cells and
enhances Th1 cell differentiation. Thus, increased IL-12
response in patients with severe sepsis may exert a pro-
tective effect by increased cellular immunity and phago-
cytic functions.
IL-10 can inhibit monocyte and macrophage proinflam-
matory cytokine production, Th1 cell differentiation and
NK cell function. A sustained high plasma IL-10 level is
the main predictor of severity and poor outcome in
patients with severe sepsis [11,18]. Our current study
shows the same results. Plasma IL-10 levels in nonsurvi-
vors with severe sepsis were higher than those in survivors
on days 1 and 7. Moreover, plasma IL-10 levels in survi-
vors significantly decreased from days 1 to 7, whereas
plasma IL-10 levels in nonsurvivors did not change. There
are reports of similar results. Ozbalkan et al. [24] detected
a second peak serum IL-10 level in nonsurvivors with
burn-induced sepsis. Stanilova et al. [9] reported low IL-
10 production after LPS stimulation in survivors with
severe sepsis. However, in our current study, we did not
find similar results. More studies are needed to elucidate
the relationship of IL-10 response with outcome in
patients with severe sepsis.
Plasma IL-6 level is also a marker for predicting infec-
tion and survival in patients with sepsis [11,25]. Above
results support the concept that IL-6 level in the early
stage of severe sepsis can be a good predictor of mortal-
ity. In our current study, plasma IL-6 levels on day 1 in
nonsurvivors were higher than those in survivors. More-
over, plasma IL-6 levels in survivors were significantly
decreased from day 1 to day 7. The decreasing trend in
plasma IL-6 levels was not found in nonsurvivors with
severe sepsis. IL-6 responses from PBMCs of survivors
significantly decreased from day 1 to day 7. This indicates
that IL-6 may be a marker, not an actual mediator, of
defense against pathogens.
Plasma TGF-b1 levels upon admission are significantly
higher in nonsurvivors of severe sepsis than in survivors
[11]. Moreover, TGF-b1 responses from PBMCs were
higher in nonsurvivors than in survivors. The anti-
inflammatory effects of TGF-b1 may act as a mediator
of sepsis-induced immunosuppression. In the current
study, there were no differences in plasma IL-17 levels
and IL-17 responses between survivors and non-
Figure 3 IL-6 response was decreased while IL-12 response was significantly increased after 6 days in survivors with severe sepsis.
There was no difference in (A) IL-6 or (B) IL-12 responses between day 1 and day 7 in nonsurvivors with severe sepsis.
Table 3 Monocyte human leukocyte antigen-DR expression in peripheral blood mononuclear cells of survivors,
nonsurvivors and controls on days 1 and 7
Patient characteristics Survivors (n = 23) Nonsurvivors (n = 11) All patients (n = 34) Controls (n = 30)
Day 1
Monocytes (%) 11.3 (0.3 to 39.8) 9.2 (2.7 to 40.5) 11.1 (0.3 to 40.5) 3.6† (1.3 to 9.5)
HLA-DR measurements of positive monocytes (%) 37.8 (1.7 to 66.8) 41.9 (22.3 to 80.7) 41.0 (1.7 to 80.7) 91.7† (57.3 to 98.4)
HLA-DR measurements (MFI) 0.9 (0.6 to 2.9) 0.8 (0.7 to 1.7) 0.9 (0.6 to 2.9) 1.8† (1.4 to 2.6)
Day 7 (n = 23) (n = 6) (n = 29)
Monocytes (%) 9.2 (1.1 to 31.7) 15.6 (3.2 to 25.7) 10.0 (1.1 to 31.7)
HLA-DR measurement of positive monocytes (%) 45.8 (11.4 to 74.9) 33.4 (18.9 to 71.9) 40.6 (11.4 to 74.9)
HLA-DR measurements (MFI) 1.2*(0.7 to 1.7) 0.9 (0.7 to 1.2) 1.1 (0.7 to 1.7)
HLA-DR = human leukocyte antigen-DR; PBMC = peripheral blood mononuclear cell; MFI = means of fluorescence intensity. Data are medians (ranges). *P = 0.004
compared with survivors on day 1 by Wilcoxon signed-rank test. †P < 0.05 compared with patients with severe sepsis by Mann-Whitney U test.
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survivors on day 1 or day 7. These results are similar to
those reported by White et al. [26]. In our present
study, plasma IL-17 levels in septic patients were higher
than those in controls, but IL-17 responses between
patients and controls were similar. IL-17 plays an
important role in infection and inflammation [27]. Thus,
septic patients need more IL-17 to help eradicate patho-
gens, and the ability to produce IL-17 did not diminish.
More investigations are needed to determine the role of
IL-17 in severe sepsis.
In this work, the capacity to produce IL-12 and TNF-a
from PBMCs of patients with severe sepsis was dimin-
ished, whereas the release of IL-10 was not affected. These
findings are well-known [3]. Plasma IL-6, IL-10 and TGF-
b1 levels were higher, and plasma IL-12 levels were lower,
in septic patients than in controls. These findings are simi-
lar to those of a previous study [11]. There is overwhelm-
ing support for increased IL-1b expression in severe
sepsis. However, anti-IL-1b treatment does not increase
survival in patients with severe sepsis [28,29]. In this work,
there was no change in plasma IL-1b level and IL-1b
response between day 1 and day 7 in survivors or nonsur-
vivors. This suggests that IL-1b is important for inflamma-
tion but is not associated with mortality.
There is one limitation in this study. Fewer than 10
nonsurvivors were alive for more than 7 days. This
result is indicative of a relatively low power of statistical
analysis in comparisons between days 1 and 7 in the
nonsurvivor group and between groups of survivors and
nonsurvivors on day 7.
Conclusions
In our present study, we found that monocyte HLA-DR
expression and IL-12 response from PBMCs recovered
in survivors of severe sepsis. The role of IL-6 in sepsis
may be as a parameter of disease severity. Persistently
high plasma IL-10 level may cause sepsis-induced
immunosuppression and death. These findings aid in
the understanding of immune system reactions during
the process of severe sepsis.
Key message
• Monocyte HLA-DR expression and IL-12 response
from PBMCs are recovered in survivors with severe
sepsis.
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